Zobrazeno 1 - 10
of 299
pro vyhledávání: '"Mathias Witzens"'
Autor:
Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Frickhofen, Maike Nickelsen, Tobias Gaska, Frank Griesinger, Rolf Mahlberg, Reinhard Marks, Ofer Shpilberg, Hans-Walter Lindemann, Martin Soekler, Ludwig Fischer von Weikersthal, Michael Kiehl, Eva Roemer, Martin Bentz, Beate Krammer-Steiner, Ralf Trappe, Peter de Nully Brown, Massimo Federico, Francesco Merli, Marianne Engelhard, Bertram Glass, Norbert Schmitz, Lorenz Truemper, Moritz Bewarder, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Heinz Schmidberger, Jochen Fleckenstein, Markus Loeffler, Viola Poeschel, Gerhard Held, on behalf of German Lymphoma Alliance (GLA)
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e904 (2023)
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18–60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index (aaI
Externí odkaz:
https://doaj.org/article/1e8a36d90cfc4a6ab52a8d26ac285de3
Autor:
Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen, Maike Nickelsen, Ofer Shpilberg, Mathias Witzens-Harig, Frank Griesinger, Beate Krammer-Steiner, Andreas Neubauer, Peter de Nully Brown, Massimo Federico, Bertram Glass, Norbert Schmitz, Gerald Wulf, Lorenz Truemper, Moritz Bewarder, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Marianne Engelhard, Heinz Schmidberger, Jochen Fleckenstein, Christian Berdel, Markus Loeffler, Marita Ziepert, on behalf of the German Lymphoma Alliance (GLA)
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e917 (2023)
UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were randomized to
Externí odkaz:
https://doaj.org/article/f39990c175e24501836e410f27b615d4
Autor:
Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e808 (2022)
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we
Externí odkaz:
https://doaj.org/article/454022e1c0504a2caa116000c0379a95
Autor:
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, Julia Wosniok, Oliver Deuster, Jennifer Klemmer, Anne-Marie Geueke, Julia Meißner, Anthony D. Ho, Johannes Atta, Reinhard Marks, Paul La Rosée, Christian Buske, Martin H. Dreyling, Georg Hess
Publikováno v:
HemaSphere, Vol 5, Iss 10, p e636 (2021)
There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the resul
Externí odkaz:
https://doaj.org/article/f4caec53eac240f28b2e2b6f489f18d4
Autor:
Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, Klaus Herfarth
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-8 (2019)
Abstract Background Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irra
Externí odkaz:
https://doaj.org/article/4257a87c396748f6be1659d0dc328543
Autor:
Georg Hess, Karola Wagner, Ulrich Keller, Paul La Rosee, Johannes Atta, Kai Hübel, Christian Lerchenmueller, Daniel Schoendube, Mathias Witzens-Harig, Christian Ruckes, Christoph Medler, Christina van Oordt, Wolfram Klapper, Matthias Theobald, Martin Dreyling
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e398 (2020)
Abstract. In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous
Externí odkaz:
https://doaj.org/article/df50cb3a9f414acba4d126da7585c1a9
Autor:
Aayushi Srivastava, Sara Giangiobbe, Abhishek Kumar, Nagarajan Paramasivam, Dagmara Dymerska, Wolfgang Behnisch, Mathias Witzens-Harig, Jan Lubinski, Kari Hemminki, Asta Försti, Obul Reddy Bandapalli
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
Hodgkin lymphoma (HL) is a lymphoproliferative malignancy of B-cell origin that accounts for 10% of all lymphomas. Despite evidence suggesting strong familial clustering of HL, there is no clear understanding of the contribution of genes predisposing
Externí odkaz:
https://doaj.org/article/8dd35bfecde94fb981e63ac60497ced8
Autor:
Klaus Herfarth, Peter Borchmann, Sven Schnaidt, Karin Hohloch, Volker Budach, Marianne Engelhard, Andreas Viardot, Rita Engenhart-Cabillic, Ulrich Keller, Gabriele Reinartz, Hans-Theodor Eich, Mathias Witzens-Harig, Clemens F. Hess, Bernd Dörken, Jan Dürig, Thomas Wiegel, Wolfgang Hiddemann, Eva Hoster, Christiane Pott, Martin Dreyling
Publikováno v:
HemaSphere, Vol 2, Iss 6 (2018)
Abstract. The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-a
Externí odkaz:
https://doaj.org/article/3b975c9773894904a30ae659e98cefb3
Autor:
Liat Vidal, Anat Gafter-Gvili, Martin Dreyling, Michele Ghielmini, Mathias Witzens-Harig, Ofer Shpilberg, Michael Unterhalt, Mathias Rummel, Ronit Gurion
Publikováno v:
HemaSphere, Vol 2, Iss 4 (2018)
Abstract. Current treatment of patient with mantle cell lymphoma (MCL) is insufficient and does not result in cure. To assess the efficacy and safety of maintenance therapy for patients with MCL, we performed a systematic review and meta-analysis of
Externí odkaz:
https://doaj.org/article/47248c88673542ec87f55becdcc24b67
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established f
Externí odkaz:
https://doaj.org/article/b4414111e8904d44bb27cca2afe89ed8